Претраживање
Приказ резултата 1-1 од 1
Potential anti-melanoma activity of Imidazoline I1 receptor agonists
(European Association for Cancer Research, 2020)
Melanoma is the deadliest form of skin cancer. Despite the advancements in targeted
BRAF and MEK therapy and immunotherapies, metastatic melanoma patients still
have poor prognosis with a median survival of 9 months ...